Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: A retrospective cohort study

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Li, Feng Yan ^a   Wu, San Gang ^b   Zhou, Juan ^b   Sun, Jia Yuan ^a   Lin, Qin ^b   Lin, Huan Xin ^a   Guan, Xun Xing ^a   He, Zhen Yu ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS FREE SURVIVAL; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY; AXILLA; BREAST NEOPLASMS; IMMUNOHISTOCHEMISTRY; LYMPH NODE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA; SURVIVAL; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AXILLA; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84896804476     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087264     Document Type: Article

References (35)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
2. Sayer HG, Kath R, Kliche KO, Hoffken K (2002) Premenopausal breast cancer: chemotherapy and endocrine therapy. Drugs 62: 2025-2038. (Pubitemid 35204035)
3. de Bono JS, Tolcher AW, Rowinsky EK (2003) The future of cytotoxic therapy: selective cytotoxicity based on biology is the key. Breast cancer research 5: 154-159. (Pubitemid 36519409)
4. Luporsi E, Andre F, Spyratos F, Martin PM, Jacquemier J, et al. (2012) Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast cancer research and treatment 132: 895-915.
5. Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. Journal of cellular physiology 182: 311-322. (Pubitemid 30054364)
6. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, et al. (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Annals of oncology 20: 1319-1329.
7. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, et al. (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of oncology 22: 1736-1747.
8. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, et al. (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. Journal of the National Cancer Institute 101: 736-750.
9. de Azambuja E, Cardoso F, de Castro G, Jr., Colozza M, Mano MS, et al. (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. British journal of cancer 96: 1504-1513. (Pubitemid 46762956)
10. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P (2008) Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 17: 323-334.
11. Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early breast cancer. Journal of clinical oncology 23: 7212-7220.
12. Neri A, Marrelli D, Pedrazzani C, Caruso S, De Stefano A, et al. (2008) Prognostic relevance of proliferative activity evaluated by Mib-1 immunostaining in node negative breast cancer. European journal of surgical oncology 34: 1299-1303.
13. Jalava P, Kuopio T, Juntti-Patinen L, Kotkansalo T, Kronqvist P, et al. (2006) Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology 48: 674-682.
14. Sullivan HC, Oprea-Ilies G, Adams AL, Page AJ, Kim S, et al. (2013) Triple-negative Breast Carcinoma in African American and Caucasian Women: Clinicopathology, Immunomarkers, and Outcome. Applied immunohistochemistry & molecular morphology
15. Xue C, Wang X, Peng R, Shi Y, Qin T, et al. (2012) Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. Cancer science 103: 1679-1687.
16. Matsubara N, Mukai H, Itoh K, Nagai S (2011) Prognostic impact of Ki-67 overexpression in subgroups categorized according to St. Gallen with early stage breast cancer. Oncology 81: 345-352.
17. Wiesner FG, Magener A, Fasching PA, Wesse J, Bani MR, et al. (2009) Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. Breast 18: 135-141.
18. Wu SG, He ZY, Li Q, Li FY, Lin Q, et al. (2012) Predictive value of breast cancer molecular subtypes in Chinese patients with four or more positive nodes after postmastectomy radiotherapy. Breast 21: 657-661.
19. Li B, Zhu Z, Wang J, Hou J, Zhao J, et al. (2004) Expression Correlation of Ki67 to P53,VEG F,and C-erbB-2 Genes in Breast Cancer and Their ClinicaI Significances, Chinese Journal of Cancer, 2004, 23(10), 1176-1179. Expression Correlation of Ki67 to P53, VEG F, and C-erbB-2 Genes in Breast Cancer and Their ClinicaI Significances, Chinese Journal of Cancer, 2004, 23(10), 1176-1179 23: 1176-1179.
20. Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, et al. (2010) Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Experimental and therapeutic medicine 1: 747-754.
21. Kruger K, Stefansson IM, Collett K, Arnes JB, Aas T, et al. (2013) Microvessel proliferation by co-expression of endothelial nestin and Ki-67 is associated with a basal-like phenotype and aggressive features in breast cancer. Breast 22: 282-288.
22. Danko ME, Bennett KM, Zhai J, Marks JR, Olson JA Jr (2010) Improved staging in node-positive breast cancer patients using lymph node ratio: results in 1,788 patients with long-term follow-up. Journal of the American College of Surgeons 210: 797-805 e791, 805-797.
23. Kelleher M, Miles D (2003) The adjuvant treatment of breast cancer. International journal of clinical practice 57: 195-199.
24. Tawfik K, Kimler BF, Davis MK, Fan F, Tawfik O (2013) Ki-67 expression in axillary lymph node metastases in breast cancer is prognostically significant. Human pathology 44: 39-46.
25. Joensuu K, Leidenius M, Kero M, Andersson LC, Horwitz KB, et al. (2013) ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer-Reduced CK5 Expression in Metastases. Breast cancer : basic and clinical research 7: 23-34.
26. Matsubara N, Mukai H, Fujii S, Wada N (2013) Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer. Breast cancer research and treatment 137: 203-212.
27. Crabb SJ, Bajdik CD, Leung S, Speers CH, Kennecke H, et al. (2008) Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study. Breast cancer research 10: R6.
28. Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, et al. (2000) Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis. Annals of surgical oncology 7: 305-311. (Pubitemid 30318320)
29. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, et al. (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Annals of oncology 18: 1133-1144. (Pubitemid 47244357)
30. Couture C, Raybaud-Diogene H, Tetu B, Bairati I, Murry D, et al. (2002) p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer 94: 713-722. (Pubitemid 34132300)
31. Park D, Karesen R, Noren T, Sauer T (2007) Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases: clinical implications. Virchows Archiv 451: 11-18.
32. Dikicioglu E, Barutca S, Meydan N, Meteoglu I (2005) Biological characteristics of breast cancer at the primary tumour and the involved lymph nodes. International journal of clinical practice 59: 1039-1044.
33. Yoshioka T, Hosoda M, Yamamoto M, Taguchi K, Hatanaka KC, et al. (2013) Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer. Breast cancer.
34. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA (2010) Ki67 in breast cancer: prognostic and predictive potential. The lancet oncology 11: 174-183.
35. Mohammed ZM, McMillan DC, Elsberger B, Going JJ, Orange C, et al. (2012) Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. British journal of cancer 106: 383-388.